Systematic Non-Invasive Experimental Analysis of Olfactory Dysfunction using EBG for COVID-19

SARS-CoV2 has encompassed showing symptoms from acute respiratory distress syndrome to minor symptoms like loss of smell, taste, fever, body ache. This paper, explains the brain activity observed, if loss of smell (Olfaction) persists. If the symptoms are treated as early biomarker will enable earlier diagnosis and preventative treatments of syndromes. The proposed framework suggests a portable, easy to deploy noninvasive method to detect olfactory dysfunctions at the COVID test center. The validation of the parameters under clinical expertise has laid a ground to predict and proper assess of olfactory deficits in a patient within 20 minutes. The selection of hyper parameters was done using RBF kernel. The test is steered using a simple neuro-imaging, non-invasive device gathering the EBG waves, essentially gamma waves received from the olfactory nerve present in the upper nostril. The results impress to establish a base, that a decreased sense of smell may be a pointer to patients in the initial stage of the syndrome. The statistical validator, Fisher’s exact test is performed for data analyses taken from neuroimaging device. The statistical significance was defined as P < .05 for the anosmia (loss of smell). The P- value calculated through our experimental setup is 0.008 for anosmia proved as a significant factor for the detection of infection.